Context matters: Tumor microenvironments impact cellular therapy success.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 38631291.
- Also identified by DOI 10.1016/j.xcrm.2024.101491 and PMC identifier 11031417.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a recent publication, Locke et al. present data from pretreatment tumor biopsies taken on the ZUMA-7 trial. Their results identify tumor microenvironment (TME) contexts and level of CD19 expression as prognostic indicators for responses to axicabtagene ciloleucel (axi-cel).
Medical subject headings
- Tumor Microenvironment
- Antigens, CD19